These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24533896)

  • 1. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial.
    Ostovaneh MR; Saeidi B; Hajifathalian K; Farrokhi-Khajeh-Pasha Y; Fotouhi A; Mirbagheri SS; Emami H; Barzin G; Mirbagheri SA
    Neurogastroenterol Motil; 2014 May; 26(5):670-8. PubMed ID: 24533896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
    Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
    Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec.
    Walker D; Ng Kwet Shing R; Jones D; Gruss HJ; Reguła J
    PLoS One; 2015; 10(2):e0116308. PubMed ID: 25706883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
    Spechler SJ; Hunter JG; Jones KM; Lee R; Smith BR; Mashimo H; Sanchez VM; Dunbar KB; Pham TH; Murthy UK; Kim T; Jackson CS; Wallen JM; von Rosenvinge EC; Pearl JP; Laine L; Kim AW; Kaz AM; Tatum RP; Gellad ZF; Lagoo-Deenadayalan S; Rubenstein JH; Ghaferi AA; Lo WK; Fernando RS; Chan BS; Paski SC; Provenzale D; Castell DO; Lieberman D; Souza RF; Chey WD; Warren SR; Davis-Karim A; Melton SD; Genta RM; Serpi T; Biswas K; Huang GD
    N Engl J Med; 2019 Oct; 381(16):1513-1523. PubMed ID: 31618539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
    Vakil NB; Huff FJ; Cundy KC
    Aliment Pharmacol Ther; 2013 Jul; 38(2):107-17. PubMed ID: 23721547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease.
    Nakamura K; Akiho H; Ochiai T; Motomura Y; Higuchi N; Okamoto R; Matsui N; Yasuda D; Akahoshi K; Kabemura T; Ihara E; Harada N; Ito T; Takayanagi R
    Hepatogastroenterology; 2010; 57(99-100):497-500. PubMed ID: 20698216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial.
    Manabe N; Haruma K; Ito M; Takahashi N; Takasugi H; Wada Y; Nakata H; Katoh T; Miyamoto M; Tanaka S
    Dis Esophagus; 2012 Jul; 25(5):373-80. PubMed ID: 22050449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.
    Galmiche JP; Barthelemy P; Hamelin B
    Aliment Pharmacol Ther; 1997 Aug; 11(4):765-73. PubMed ID: 9305487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
    Vakil NB; Huff FJ; Bian A; Jones DS; Stamler D
    Am J Gastroenterol; 2011 Aug; 106(8):1427-38. PubMed ID: 21519360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn.
    Martinucci I; de Bortoli N; Savarino E; Piaggi P; Bellini M; Antonelli A; Savarino V; Frazzoni M; Marchi S
    Neurogastroenterol Motil; 2014 Apr; 26(4):546-55. PubMed ID: 24433456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.
    Richter JE; Kahrilas PJ; Sontag SJ; Kovacs TO; Huang B; Pencyla JL
    Am J Gastroenterol; 2001 Nov; 96(11):3089-98. PubMed ID: 11721754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
    Shimatani T; Sugimoto M; Nishino M; Adachi K; Furuta K; Ito M; Kurosawa S; Manabe N; Mannen K; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol Hepatol; 2012 May; 27(5):899-906. PubMed ID: 22098590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial.
    Hunter JG; Kahrilas PJ; Bell RC; Wilson EB; Trad KS; Dolan JP; Perry KA; Oelschlager BK; Soper NJ; Snyder BE; Burch MA; Melvin WS; Reavis KM; Turgeon DG; Hungness ES; Diggs BS
    Gastroenterology; 2015 Feb; 148(2):324-333.e5. PubMed ID: 25448925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
    Kahrilas PJ; Hughes N; Howden CW
    Gut; 2011 Nov; 60(11):1473-8. PubMed ID: 21508423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial.
    Limsrivilai J; Charatcharoenwitthaya P; Pausawasdi N; Leelakusolvong S
    Am J Gastroenterol; 2016 Feb; 111(2):217-24. PubMed ID: 26753892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials.
    Peura DA; Traxler B; Kocun C; Lind T
    Postgrad Med; 2014 Jul; 126(4):33-41. PubMed ID: 25141241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response.
    Lind T; Havelund T; Carlsson R; Anker-Hansen O; Glise H; Hernqvist H; Junghard O; Lauritsen K; Lundell L; Pedersen SA; Stubberöd A
    Scand J Gastroenterol; 1997 Oct; 32(10):974-9. PubMed ID: 9361168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.